婴儿痉挛药物市场规模、份额、成长分析（按治疗剂、按类型、按形式、按给药途径、按最终用户、按分销渠道、按地区）- 行业预测 2025-2032

2023 年全球婴儿痉挛治疗市场规模为 1.4 亿美元，预计将从 2024 年的 1.4924 亿美元增长到 2032 年的 2.4885 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.6%。

根据市场发展洞察，全球对婴儿痉挛药物的需求受到已开发市场和新兴市场日益增长的盛行率的推动。小儿科意识的提高和研发方面的大量投资正在推动收益成长，而药物配方的进步和儿科神经病学服务的扩展正在改善这些治疗的机会。先进的脑电图、核磁共振成像和基因序列测定等创新工具正在促进早期诊断。政府医疗保健计划和非营利组织的支持有助于提高人们对罕见儿童神经系统疾病的认识并筹集更多资金。然而，治疗费用上升、训练有素的专家短缺、现有治疗方法可能产生的副作用以及欠发达地区缺乏诊断等挑战可能会阻碍未来的市场销售。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

婴儿痉挛治疗市场规模（按治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 抗惊厥药
• 皮质类固醇
• 其他的

婴儿痉挛药物市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• Vigabatrin
• 促肾上腺皮质激素
• 第三阶段

婴儿痉挛治疗市场规模（按类型及复合年增长率） (2025-2032)

• 市场概览
• 固体的
• 液体

婴儿痉挛治疗市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概览
• 口服
• 肠外
• 其他的

婴儿痉挛药物市场规模（按最终用户和复合年增长率）（2025-2032）

• 市场概览
• 诊所
• 医院
• 其他的

婴儿痉挛药物市场规模（依分销管道和复合年增长率）（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局

婴儿痉挛治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Amneal Pharmaceuticals LLC（US）
• Cipla（India）
• Endo, Inc.（US）
• H. Lundbeck A/S（Denmark）
• Hetero（India）
• Intas Pharmaceuticals Ltd.（India）
• Jazz Pharmaceuticals, Inc.（Ireland）
• Mallinckrodt（Ireland）
• MSN Laboratories（India）
• Ovid Therapeutics（US）
• SGPharma Pvt. Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Zydus Group（India）
• Merz Therapeutics（US）
• Ionis Pharmaceuticals（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Eisai Co., Ltd.（Japan）

结论和建议

Global Infantile Spasms Therapeutics Market size was valued at USD 140.0 million in 2023 and is poised to grow from USD 149.24 million in 2024 to USD 248.85 million by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

Market insights indicate a rising global demand for infantile spasms therapeutics, driven by an increasing prevalence of the condition in both developed and developing regions. Enhanced awareness among pediatricians and significant investments in R&D are propelling revenue growth, while advancements in drug formulations and the expansion of pediatric neurology services improve access to these therapies. Innovative tools such as advanced EEG, MRI, and genetic sequencing are facilitating earlier diagnoses. Support from government healthcare programs and nonprofit organizations is further amplifying awareness and funding for rare pediatric neurological disorders. However, challenges such as high treatment costs, a scarcity of trained specialists, potential side effects of existing treatments, and underdiagnosis in less developed areas may hinder market sales in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infantile Spasms Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infantile Spasms Therapeutics Market Segments Analysis

Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infantile Spasms Therapeutics Market

The increasing awareness among the medical community regarding infantile spasms has significantly improved the speed of diagnosis and treatment. Pediatricians and general practitioners are now more knowledgeable about the condition's symptoms and the critical need for prompt intervention, resulting in quicker referrals to specialists for suspected cases. This heightened clinical awareness has accelerated therapeutic responses, minimizing long-term neurodevelopmental impairment and promoting a greater reliance on therapeutics designed for infantile spasms. Consequently, this trend is driving growth in the global market for infantile spasms therapeutics, as more healthcare providers prioritize timely and effective care for affected infants.

Restraints in the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market faces notable challenges due to the substantial side effects associated with treatments such as ACTH and vigabatrin. Adverse effects including adrenal suppression, vision loss, and immune suppression often create hesitation among healthcare providers and parents regarding the initiation of therapy. This apprehension can result in premature discontinuation or outright avoidance of treatment, especially in borderline cases. Additionally, the lack of safer long-term alternative therapies exacerbates these concerns, impacting overall treatment compliance and limiting the market's growth potential. Hence, these factors represent a significant restraint within the sector.

Market Trends of the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market is witnessing a significant shift towards precision medicine and genetic profiling, driven by advances in molecular diagnostics. This trend underscores the importance of personalized treatment strategies, with genetic testing and next-generation sequencing playing crucial roles in identifying the underlying causes of infantile spasms. As these technologies become more affordable and accessible, pharmaceutical companies are increasingly investing in mutation-targeted therapies, enhancing the effectiveness of treatments. This strategic focus on tailored approaches is expected to shape the future of the market, leading to improved patient outcomes and fostering innovation in therapeutic options for infantile spasms.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Infantile Spasms Therapeutics Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Anticonvulsants
• Corticosteroids
• Others

Global Infantile Spasms Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Vigabatrin
• Adrenocorticotropic Hormone
• Phase III

Global Infantile Spasms Therapeutics Market Size by Dosage & CAGR (2025-2032)

• Market Overview
• Solid
• Liquid

Global Infantile Spasms Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Infantile Spasms Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Clinic
• Hospital
• Others

Global Infantile Spasms Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Infantile Spasms Therapeutics Market Size & CAGR (2025-2032)

• North America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amneal Pharmaceuticals LLC (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals, Inc. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGPharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merz Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations